DE602004017966D1 - Neue aminopyridinderivate als mglur5-antagonisten - Google Patents
Neue aminopyridinderivate als mglur5-antagonistenInfo
- Publication number
- DE602004017966D1 DE602004017966D1 DE602004017966T DE602004017966T DE602004017966D1 DE 602004017966 D1 DE602004017966 D1 DE 602004017966D1 DE 602004017966 T DE602004017966 T DE 602004017966T DE 602004017966 T DE602004017966 T DE 602004017966T DE 602004017966 D1 DE602004017966 D1 DE 602004017966D1
- Authority
- DE
- Germany
- Prior art keywords
- pyridine derivatives
- new amino
- mglur5 antagonists
- mglur5
- antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0304901A GB0304901D0 (en) | 2003-03-04 | 2003-03-04 | Novel aminopyridine derivatives as mGIuR5 antagonists |
| GB0316430A GB0316430D0 (en) | 2003-07-14 | 2003-07-14 | Aminopyridine derivatives |
| PCT/IB2004/000745 WO2004078728A1 (en) | 2003-03-04 | 2004-03-04 | NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004017966D1 true DE602004017966D1 (de) | 2009-01-08 |
Family
ID=32964064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004017966T Expired - Lifetime DE602004017966D1 (de) | 2003-03-04 | 2004-03-04 | Neue aminopyridinderivate als mglur5-antagonisten |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7205411B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2028180A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006519251A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE415390T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004218180B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2517083A1 (cg-RX-API-DMAC7.html) |
| CY (1) | CY1108837T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE602004017966D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1603877T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2316968T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL1603877T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1603877E (cg-RX-API-DMAC7.html) |
| RU (1) | RU2330020C2 (cg-RX-API-DMAC7.html) |
| SI (1) | SI1603877T1 (cg-RX-API-DMAC7.html) |
| UA (1) | UA81464C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004078728A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0413605D0 (en) | 2004-06-17 | 2004-07-21 | Addex Pharmaceuticals Sa | Novel compounds |
| AU2006240217A1 (en) * | 2005-04-22 | 2006-11-02 | Merck & Co., Inc. | Phenyl ethyne compounds |
| WO2007035823A2 (en) * | 2005-09-20 | 2007-03-29 | Molecular Neuroimaging, Llc | Partial mglur5 antagonists and methods of use thereof |
| DE102005062987A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| EP2272509A1 (en) * | 2006-09-11 | 2011-01-12 | Novartis AG | New Uses of metabotropic glutamate receptors |
| EA201391348A8 (ru) | 2011-03-18 | 2014-11-28 | Новартис Аг | КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6028963A (ja) * | 1983-07-27 | 1985-02-14 | Takeda Chem Ind Ltd | 置換ビニル誘導体 |
| TW544448B (en) | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| DE10009000A1 (de) | 2000-02-25 | 2001-08-30 | Basf Ag | Verfahren zur Herstellung substituierter Indole |
| NZ525917A (en) | 2000-12-04 | 2005-11-25 | F | Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists and their use in treating mGLuR5 receptor mediated disorders |
-
2004
- 2004-03-04 JP JP2006506343A patent/JP2006519251A/ja active Pending
- 2004-03-04 DE DE602004017966T patent/DE602004017966D1/de not_active Expired - Lifetime
- 2004-03-04 RU RU2005130647/04A patent/RU2330020C2/ru not_active IP Right Cessation
- 2004-03-04 WO PCT/IB2004/000745 patent/WO2004078728A1/en not_active Ceased
- 2004-03-04 PL PL04717193T patent/PL1603877T3/pl unknown
- 2004-03-04 PT PT04717193T patent/PT1603877E/pt unknown
- 2004-03-04 EP EP08018437A patent/EP2028180A1/en not_active Withdrawn
- 2004-03-04 DK DK04717193T patent/DK1603877T3/da active
- 2004-03-04 SI SI200431006T patent/SI1603877T1/sl unknown
- 2004-03-04 EP EP04717193A patent/EP1603877B1/en not_active Expired - Lifetime
- 2004-03-04 AU AU2004218180A patent/AU2004218180B2/en not_active Ceased
- 2004-03-04 UA UAA200508498A patent/UA81464C2/xx unknown
- 2004-03-04 CA CA002517083A patent/CA2517083A1/en not_active Abandoned
- 2004-03-04 AT AT04717193T patent/ATE415390T1/de not_active IP Right Cessation
- 2004-03-04 ES ES04717193T patent/ES2316968T3/es not_active Expired - Lifetime
-
2005
- 2005-09-02 US US11/225,490 patent/US7205411B2/en not_active Expired - Fee Related
-
2007
- 2007-03-13 US US11/717,860 patent/US20080004316A1/en not_active Abandoned
-
2009
- 2009-02-26 CY CY20091100218T patent/CY1108837T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004218180B2 (en) | 2009-11-12 |
| EP1603877A1 (en) | 2005-12-14 |
| DK1603877T3 (da) | 2009-03-09 |
| RU2330020C2 (ru) | 2008-07-27 |
| US20080004316A1 (en) | 2008-01-03 |
| ES2316968T3 (es) | 2009-04-16 |
| PT1603877E (pt) | 2009-02-11 |
| EP2028180A1 (en) | 2009-02-25 |
| RU2005130647A (ru) | 2006-04-10 |
| US20060030601A1 (en) | 2006-02-09 |
| UA81464C2 (en) | 2008-01-10 |
| CA2517083A1 (en) | 2004-09-16 |
| ATE415390T1 (de) | 2008-12-15 |
| AU2004218180A1 (en) | 2004-09-16 |
| PL1603877T3 (pl) | 2009-05-29 |
| EP1603877B1 (en) | 2008-11-26 |
| SI1603877T1 (sl) | 2009-04-30 |
| WO2004078728A1 (en) | 2004-09-16 |
| CY1108837T1 (el) | 2014-07-02 |
| US7205411B2 (en) | 2007-04-17 |
| JP2006519251A (ja) | 2006-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69318854D1 (de) | Spiroazacyclischderivate als substanz p antagonisten | |
| EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
| DE69328975D1 (de) | Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten | |
| DE602004017213D1 (de) | Allosterische modulatoren von metabotropen glutamatrezeptoren | |
| MY135686A (en) | Indole derivatives useful as histamine h3 antagonists | |
| EA200700047A1 (ru) | Новые алкильные производные в качестве метаботропных рецепторов глутамата | |
| SE0201635D0 (sv) | Novel compounds | |
| DE69616480D1 (de) | Piperidinderivate als neurokininantagonisten | |
| CY1111858T1 (el) | Ετεροκυκλικα παραγωγα ως διαμορφωτες υποδοχεα οπιοειδων | |
| ATE387199T1 (de) | Neue substanzen und verbindungen als protease- inhibitoren | |
| DE602005025672D1 (de) | Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren | |
| DE69838662D1 (de) | Morphinanderivate und ihre medizinische Anwendung | |
| ATE392415T1 (de) | 3-azabicyclo(3.1.0)hexan derivative als antagonisten der opioid rezeptoren | |
| CY1108837T1 (el) | ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5 | |
| EA200801734A1 (ru) | Производные n-тиазол-2-илбензамида | |
| ATE429421T1 (de) | Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten | |
| BR0307156A (pt) | Derivado de pirimidina bicìclica fundida, composto, antagonistas de receptores e agentes profiláticos e terapêuticos | |
| BG105710A (en) | 5ht1 antagonists for antidepressant therapy | |
| DK1254905T3 (da) | 4-(2-pyridyl)piperiziner med 5HT7 receptoragonistaktivitet | |
| NO20081529L (no) | Naftyridinderivater | |
| TR200001080T2 (tr) | 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri | |
| ATE383343T1 (de) | Imidazolderivate verwendbar als histamin h3 rezeptorliganden | |
| EP1496059A4 (en) | CONDENSED BICYCLIC PYRIMIDINE DERIVATIVES | |
| EA200401099A1 (ru) | Производные гетероциклического амида | |
| ATE283269T1 (de) | 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |